Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast04: neoadjuvant Dato-DXd + durvalumab versus pembrolizumab + chemotherapy in untreated TNBC or HR-low/HER2-negative breast cancer
CTR20240839Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab and pembrolizumab in triple-negative breast cancer (TNBC) and Estrogen receptor-low positive breast cancer (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Event-free survival. Started Apr 2024; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)Estrogen receptor-low positive breast cancer
Beyond the preview
Go deeper on CTR20240839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240839.